Greater unavailability of generic veterinary medicine in desired dosage forms for optimum efficiency is boosting the global demand for compounded animal drugs. In addition to this, re-emergence of animal drug compounding offers valuable benefits to the pet owners, not just manufacturers. Persistence Market Research predicts that the global market for animal drug compounding, which is presently valued at US$ 844.2 Mn, will expand at 6.3% CAGR to bring in revenues worth US$ 1,373.8 Mn by end of 2024.
During this forecast period, the market’s growth will be favored by informed decisions taken by pet owners, higher level of veterinary care expected by them and lack of scientific evidence to report adverse effects of compounded animal drugs.
According to Persistence Market Research’s report, titled “Animal Drug Compounding Market: Global Industry Analysis and Forecast, 2016-2024,” more than two-third of global sales of compounded animal drugs will remain concentrated in the US and Canada. North America’s animal drug compounding market is projected to witness revenue growth at 7% CAGR. On the other hand, other parts of the world will record sluggish growth in demand for animal drug compounding as value CAGRs in these regions are less likely to reach 5%.
To Remain ‘Ahead’ of your competitors, Request for a Sample here @ https://www.persistencemarketresearch.com/samples/12871
Global Animal Drug Compounding Market: Key Opportunities
The report cites that the popularity of alternate flavored dosage forms will favor the adoption of animal drug compounding. Veterinary drug compounders try to remove the bitter taste of the medicine and make it feel non-gritty, smooth, creamy thus contributing largely towards improved patient compliance. The better the ability of a compounding pharmacist in creating flavored dosages, the greater are the future revenue-generating opportunities for manufacturers.
- Triangle Compounding Pharmacy Inc.
- Lorraine’s Pharmacy
- Medisca Inc.
- WEDGEWOOD PHARMACY
- Diamondback Drugs LLC
- Slade Dispensary Services
- ESSENTIAL PHARMACY COMPOUNDING VET (Kohll’s Pharmacy & Homecare)
For Critical Insights On The Animal Drug Compounding Market, Request For Customization Here @ https://www.persistencemarketresearch.com/request-customization/12871
Availability of accreditation also enhanced sales prospects of compounded animal drugs. In the event of adverse events not being recorded, animal owners generally prefer to visit only accredited compounding pharmacies. In addition to this, lower availability of generic substitutes to veterinary drugs also propels the practice of compounding veterinary pharmaceuticals.
Currently there is no reimbursement available for veterinary drugs, which indicate most of the drug expense goes out of pockets of animal owners. In such circumstances, most animal owners prefer resorting to compounded animal medications that are easily available, cheaper than branded equivalents and do not require multiple prescriptions.
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/12871
Global Animal Drug Compounding Market – Top Report Excerpts
- In the due course of forecast period, the global animal drug compounding market will witness impressive growth for products namely, CNS agents, anti-infective agents, and hormonal drugs
- While CNS agents will account for over 37% share of global revenues, global sales of anti-infective agents will record revenue growth at 7.8% CAGR
- Companion animals will account for 47% of global animal drug compounding revenues throughout the forecast period, and dogs will be procuring highest usage of compounded drugs for companion animals
- More than half of the market’s worth will be accounted by sales of compounded drugs for livestock animals, but their market presence will incur a decline towards the end of 2024
- Through 2024, more than 80% of the global animal drug compounding market value will be attributed by orally-formulated drugs
More About the Report –
Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.
The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Molecular Diagnostics Market –
Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.
Next-Generation Sequencing Market –
Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.
Ophthalmology devises Market –
Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.
Intravenous Iron Drugs Market –
Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.
Syndromes Progressive Ataxia Weakness Disorders Market –
Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.